AI Agent Operational Lift for Fivos in West Lebanon, New Hampshire

Why AI matters at this scale

Fivos (formerly Medstreaming) occupies a unique niche in healthcare IT, providing a specialized clinical data management platform for vascular, cardiac, and interventional radiology. Founded in 2006 and headquartered in West Lebanon, NH, the company serves hospitals and medical device manufacturers by powering clinical registries, outcomes analytics, and workflow automation. With an estimated 201-500 employees and annual revenue around $45M, Fivos is a classic mid-market vertical SaaS player—large enough to possess a meaningful data asset but agile enough to pivot faster than enterprise EHR vendors.

At this size, AI is not a luxury but a strategic imperative. The company sits on years of structured, high-quality clinical data—exactly the fuel that modern machine learning models require. Unlike general-purpose health IT firms, Fivos's deep focus on vascular and cardiac care means its datasets are coherent and clinically meaningful. The shift from fee-for-service to value-based care is accelerating demand for predictive analytics that can identify high-risk patients before adverse events occur. For a company of Fivos's scale, embedding AI into its existing platform represents a capital-efficient path to creating a new revenue tier without the overhead of building entirely new products from scratch.

Three concrete AI opportunities

1. Predictive complication risk scoring. Fivos can train models on its registry data to forecast patient-specific risks for outcomes like restenosis, surgical site infections, or readmission. This moves the platform from retrospective reporting to prospective intervention. The ROI is direct: hospitals using such scores can reduce costly complications, and Fivos can charge a premium per-patient or per-model fee, potentially adding $5-10M in annual recurring revenue.

2. Automated clinical abstraction. Manual data entry into registries is a major pain point. By applying NLP and computer vision to ingest unstructured EHR notes, PDFs, and imaging reports, Fivos could cut abstraction time by 70%. This strengthens the core value proposition, reduces customer churn, and allows the company to reallocate abstraction staff to higher-value analytics services.

3. Real-time clinical decision support. Embedding AI-driven treatment recommendations directly into the EHR workflow—suggesting optimal stents, medications, or follow-up intervals based on registry outcomes—would transform Fivos from a documentation tool into an indispensable point-of-care partner. This deepens integration and creates a powerful upsell path.

Deployment risks and mitigation

For a mid-market firm, the primary risks are regulatory, technical, and ethical. The FDA's evolving framework for Software as a Medical Device (SaMD) means predictive models that influence clinical decisions could require clearance. Fivos should start with non-diagnostic decision support tools that present risk scores without dictating treatment, staying below the regulatory threshold. Data privacy is paramount; all model training must occur within HIPAA-compliant environments, ideally using federated learning techniques that keep patient data within hospital firewalls. Finally, bias in training data could lead to unequal performance across demographics. Proactive fairness audits and diverse data sourcing are essential to avoid reputational and legal harm. By tackling these risks head-on with a dedicated, small AI team, Fivos can turn its data moat into an enduring competitive advantage.